title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
References | PMC10227122 | |||
Subject terms | depressive disorder, depression, MDD, depressed | Major depressive disorder (MDD) is the most prevalent form of depression and is becoming a great challenge for public health and medical practice. Although first-line antidepressants offer therapeutic benefits, about 35% of depressed patients are not adequately treated, creating a substantial unmet medical need. A mult... | PMC10171157 | |
Introduction | overdose, toxicity, hyperactivity, depressive disorder, MDD, depression, depressive disorders | DYSFUNCTION, ADVERSE EFFECT, REMISSION, GENOTOXICITY, PATHOGENESIS | Major depressive disorder (MDD) is one of the most common depressive disorders, with an estimated 12-month prevalence rate of 6.6% and a lifetime prevalence rate of 16.2% [The pathogenesis of MDD is complex, including structure and function alterations of discrete brain regions, especially the hippocampus [Currently, m... | PMC10171157 |
Materials and methods | PMC10171157 | |||
Study design | The study was a phase 3, multicenter, double-blind, randomized, fixed-dose, placebo-controlled clinical trial. The trial was conducted at 22 centers in China from December 2018 to December 2020. It was performed in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki. All patients pr... | PMC10171157 | ||
Participants | allergic, seizures, gastrointestinal disease, febrile convulsions, depressive disorder, MDD, psychotic disorders, DSM-5 | SECONDARY, CHRONIC DISEASES, GASTROINTESTINAL DISEASE, FEBRILE CONVULSIONS | Participants were eligible if they were male and female outpatients aged 18 to 65 years with a diagnosis of MDD, meeting the DSM-5 (Exclusion criteria for all participants were: any other psychotic disorders (except for MDD); depressive disorder secondary to other mental illnesses or physical illnesses as well; be alle... | PMC10171157 |
Procedures | depression | The study comprised a 1-week screening period and a 8-week double-blind treatment period (DBTP). During the screening period, the patients underwent physical examination, depression scale evaluations, 12-lead ECG, and laboratory examinations.Eligible patients were randomized at a 1:1:1 ratio to ansofaxine 80 mg/da y, 1... | PMC10171157 | |
Outcomes | Suicide ideation | ADVERSE EVENTS | The primary efficacy endpoint was the change of MADRS total score from baseline to the end of week 8. Secondary efficacy endpoints were the changes from baseline of the following scores at the end of week 8: Hamilton Rating Scale for Depression-17 item (HAM-DSafety assessments included adverse events (AEs), withdrawal ... | PMC10171157 |
Sample size | Sample size estimates were based on the primary efficacy endpoint, MADRS total score changes from baseline, referred to phase II clinical trial result and calculated by PASS 15 software (NCSS, LLC, USA). 140 patients were calculated in each group. Considering a 25% drop-out rate, 186 subjects were planned in each group... | PMC10171157 | ||
Blinding | Patients, clinicians, and independent outcome raters were masked to treatment allocation, and tablets in each group were identical in package and appearance. The database was locked when the final visit of the last randomized patient was completed, data entry for all patients was completed, and the database for all pat... | PMC10171157 | ||
Statistical analysis | ADVERSE EVENTS | Statistical analysis was performed using SAS®9.4 (SAS Institute, Cary, NC, USA). Continuous data were summarized in terms of the mean and standard deviation (SD). Categorical variables were summarized in terms of frequency and percentages. The efficacy analysis was based on the full analysis set (FAS), and the safety a... | PMC10171157 | |
Results | PMC10171157 | |||
Study design and flow diagram. | ADVERSE EVENT | AE, adverse event. | PMC10171157 | |
The Changes from baseline in MADRS total score (FAS). | ** indicates | PMC10171157 | ||
Secondary efficacy endpoints | The adjusted mean changes from baseline in the HAM-DA statistical significance was observed in the mean changes of CGI-S score, HAMA total score, and SDS total score from baseline for both dosages of ansofaxine CGI-I and CGI-S scores differed significantly for ansofaxine in both dose groups | PMC10171157 | ||
Distribution of CGI-I score and CGI-S score at the last observation (FAS). | FAS, full analysis set; CGI-I, Clinical Global Impressions-Improvement. CGI-S, Clinical Global Impressions-Severity.MADRS response rate at the end of week 8 was achieved in 79.89%, 73.91%, and 42.39% in the ansofaxine 80 mg, 160 mg, and placebo groups, respectively. The difference reached a statistical significance for... | PMC10171157 | ||
Safety | diarrhoea, Headache, nausea, abdominal pain, palpitations, dysphoria, paresthesia, TEAEs, constipation, dizziness, sexual dysfunction, insomnia, headache, abortion, depression, deaths, nausea, vomiting | ADVERSE EVENTS, PARESTHESIA, WOUND INFECTION, SPINAL OSTEOARTHRITIS, ECTOPIC PREGNANCY, EVENTS | TEAEs were reported by 137 (74.46%) patients in the ansofaxine 80 mg group, 144 (78.26%) patients in the ansofaxine 160 mg, and 125 (67.93%) patients in the placebo group. Most TEAEs were mild or moderate in severity. Fourteen subjects had severe TEAEs, reported by 4 (2.17%, 5 events), 4 (2.17%, 6 events), and 6 (3.26%... | PMC10171157 |
Discussion | Sexual dysfunction, anhedonia, anxiety, TEAEs, hypomanic/manic, Psychiatric disorders, psychosis, psychiatric, MDD | SIDE EFFECT, DISORDERS, ADVERSE EFFECTS, SECONDARY, REMISSION | On the primary outcome measure of changes from baseline in MADRS total score, the superiority of both dosages of ansofaxine to placebo was statistical significance, with a prominent mean treatment difference of −5.46 points for 80 mg/day and −5.06 points for 160 mg/day. However, the change in the total MADRS score from... | PMC10171157 |
Limitations | MDD | Limitations of our study include the need for more active controls, the size of the sample, the short duration of treatment, and strict inclusion and exclusion criteria that may limit the generalizability of the results. Additional demographic factors (e.g., the age of participants and the proportion of the first episo... | PMC10171157 | |
Supplementary information | The online version contains supplementary material available at 10.1038/s41398-023-02435-0. | PMC10171157 | ||
Author contributions | Jicai, CJD | RECRUITMENT, DISORDERS, CJD, BRAIN | ZHY, TJW had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. The protocol design was attributed to all of the authors. DXL, XXF, WHN, WGQ, ZKR, TF, LJ, YCJ, ZYF, XSP, ZH, WB, YD, CZH, LY, CJD, LSY, and YQZ contributed to participant re... | PMC10171157 |
Funding | This study was supported by grants from the National Science and Technology (no. 2009ZX09103-100, 2013ZX09402201-002, 2017GSF218106, 2018ZX09303015, and 2021ZD0204004). Shandong Luye Pharmaceutical Co., Ltd, is the sponsor, it provided the clinical trial funds and ansofaxine ER tablets and its placebo for the clinical ... | PMC10171157 | ||
Competing interests | The authors declare no competing interest. | PMC10171157 | ||
References | PMC10171157 | |||
Background | Physical activity in female employees is a healthy behavior and increases strength, endurance, improves flexibility, improves the feeling of vitality and freshness, improves health, and ultimately increases life expectancy. Health messages are one of the most effective ways to engage people and motivate them to perform... | PMC10666411 | ||
Method | In this interventional study, 90 of female employees of three universities and higher education institutions of Ahvaz city were selected by random sampling and randomly divided into three groups (30 participants) receiving gain framed messages, receiving loss framed messages and the control group. The tools of data col... | PMC10666411 | ||
Results | The results showed that there was a significant increase in the average physical activity score after the intervention in two interventional groups. by comparing the increase of this score, 53% improvement in physical activity is observed in the gain message group and 15% in loss massage group but there was no signific... | PMC10666411 | ||
Conclusion | The results of this study showed that the design and implementation of education programs based on message framing, especially gain framed messages through online education (Whatsapp) can improve and promote physical activity behavior in women employees. | PMC10666411 | ||
Keywords | PMC10666411 | |||
Introduction | Women’s health is one of the priorities of every society. Therefore, promoting and ensuring women’s health is one of the important pillars of the progress of societies and should always be paid attention to [ | PMC10666411 | ||
Methods | PMC10666411 | |||
Study design and setting | This study was taken from the research plan approved with the code of ethics IR.ACECR.AVICENNA.REC.1399.028. This research a three-group intervention study, including a control group and two case groups. The number of samples was used to calculate the sample size in the Pocock analytical studies. The sample size calcul... | PMC10666411 | ||
Data collection tools | The data collection tool was 2 questionnaires, including a researcher-made questionnaire based on the message framing model and the International Physical Activity Questionnaire (IPAQ), which estimated women’s physical activity in the last week in terms of MET-minutes/week. This questionnaire contains 27 items and its ... | PMC10666411 | ||
Data analysis | Data were analyzed using SPSS software version 26. Descriptive statistics such as mean ± Standard Deviation (SD), frequency and percentage for (qualitative variables) were used to describe the quantitative and qualitative variables. one-way analysis of variance, Pearson’s correlation coefficient, Repeated Measure, Pair... | PMC10666411 | ||
Discussion | According to the results of this study, the studied groups, including the groups that received gain messages, loss messages, and control groups, did not have any difference in physical activity behavior before intervention. Also, immediately after educational intervention, there was no difference in the physical activi... | PMC10666411 | ||
Conclusion | The present study was designed and conducted in order to survey the effect of education based on the framing of educational messages through mobile phone (WhatsApp) on the physical activity improve of female employees of universities and higher education institutions in Ahvaz. The results obtained from this study showe... | PMC10666411 | ||
Acknowledgements | This article is taken from the research plan approved with the code of ethics IR.ACECR.AVICENNA.REC.1399.028. The researchers sincerely thank all those who cooperated with the research team in conducting this study. | PMC10666411 | ||
Authors’ contributions | Ghodratollah Shakerinejad contributed to the study design, performing statistical analysis, Zahra Baji performing statistical analysis and revising the manuscript. Masoumeh Tehrani contributed to data collection, study design, Farzaneh Jarvandi contributed to performing statistical analyses. Maria Cheraghi manuscript d... | PMC10666411 | ||
Funding | Academic Center for Education, Culture and Research (ACECR)- Khuzestan, Ahvaz, Iran funded the study code 20-3088. The fund was spent on preparing materials such as questionnaires and data collection. | PMC10666411 | ||
Data Availability | The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. | PMC10666411 | ||
Declarations | PMC10666411 | |||
Ethics approval and consent to participate | The study was approved by the Ethics Committee of ACECR- Khuzestan, Ahvaz, Iran (Registration IR.ACECR.AVICENNA.REC.1399.028). All methods were carried out in accordance with declaration of Helsinki. Written informed consent obtained from participants. In this study, female employees were adults and none were under 16 ... | PMC10666411 | ||
Conflict of interest | The authors declare no conflict of interest. | PMC10666411 | ||
Consent for publication | Not applicable. | PMC10666411 | ||
References | PMC10666411 | |||
1. Introduction | Following the recent deployment of fifth-generation (5G) radio frequencies, several questions about their health impacts have been raised. Due to the lack of experimental research on this subject, the current study aimed to investigate the bio-physiological effects of a generated 3.5 GHz frequency. For this purpose, th... | PMC10530694 | ||
2. Materials and Methods | PMC10530694 | |||
2.1. Volunteers | RECRUITMENT | Thirty-four healthy volunteers (seventeen males and seventeen females with a mean ± standard deviation [SD] age of 26.6 ± 4.7 years and a mean ± SD body mass index of 23.3 ± 4.1 kg/mThe experimental protocol (ID-RCB n°:2020-A03127-32) was approved by the French national ethical committee “CPP Sud-Ouest et Outre-Mer 1”,... | PMC10530694 | |
2.2. Study Design and Experimental Protocol | The study was triple-blinded for the volunteers, the experimenter (L.J.), and the data analysts (L.J. and L.Y.C.). All participants underwent two counterbalanced cross-over and randomised “real” and “sham” exposure sessions. B.S. determined the random allocation, whereas L.H. ensured the blinding process.The time inter... | PMC10530694 | ||
2.4. Signal Acquisition and Data Processing | blinks | BRAIN | The EEGs were recorded in a dimly lit and electrically shielded room with a wakeful resting state, using a 64-channel cap (actiCAP-Snap, EASYCAP GmbH, Brain Products GmbH, Wörthsee, Germany) with active electrodes (actiCAP-slim electrodes, EASYCAP GmbH, Brain Products GmbH, Wörthsee, Germany). The 64 electrodes (Fp1, F... | PMC10530694 |
2.5. Statistical Analysis | The sample size was calculated with the G*power software (version 3.1.9.2), considering a statistical inference of 80% power with a medium effect size (0.5) and 95% confidence interval for analysis of variance (ANOVA) F-tests.Following data processing and curation, statistical tests were conducted using a customised MA... | PMC10530694 | ||
3. Results | As mentioned in the statistical plan, we conducted a three-way repeated-measures ANOVA—5G exposure (Factor 1: “real” vs. “sham” conditions), time period (Factor 2: baseline vs. exposure or post-exposure phases), and eye condition (Factor 3: EO vs. closed EC)—on each brain wave frequency band. We present the findings of... | PMC10530694 | ||
3.1. Beta Spectral Power | PMC10530694 | |||
3.1.1. 5G Exposure (Factor 1) | The three-way ANOVA showed no significant difference between “real” and “sham” sessions (Factor 1) in the overall studied electrodes, except for Fp1 ( | PMC10530694 | ||
3.1.2. Time Period (Factor 2) | Moreover, regarding the effect of the time period, there was no significant difference between the baseline and the exposure periods following three-way ANOVA. Likewise, when we compared the baseline and post-exposure periods, only the AFz ( | PMC10530694 | ||
3.1.3. Eye Condition (Factor 3) | Regarding the eye condition, the difference was notably significant in 40 out of 64 electrodes when comparing the baseline and exposure periods (Fp1, Fp2, AF7, AF3, AFz, AF4, AF8, F7, F5, F3, F1, F2, F4, F6, F8, FT9, FT7, FC5, FC3, FC2, FC4, FC6, FT8, FT10, T7, C5, T8, Pz, P2, P4, P6, PO7, PO3, Poz, PO4, PO8, O1, Oz, O... | PMC10530694 | ||
3.1.4. Interaction among Factors | Regarding the interaction of 5G exposure with other factors, only T7 ( | PMC10530694 | ||
3.2. Alpha Spectral Power | PMC10530694 | |||
3.2.1. 5G Exposure (Factor 1) | There was no significant change in the studied electrodes due to the 5G factor following the three-way ANOVA, except for the AF7 electrode (Following the one-way ANOVA of the baseline-corrected data, the PSD values of the overall electrodes were not significantly different between “real” and “sham” exposures, except fo... | PMC10530694 | ||
3.2.2. Time Period (Factor 2) | Concerning the time period, the comparison of the baseline and exposure periods showed 51 significant electrodes following the three-way ANOVA (F3, F1, F2, F4, F6, F8, FT9, FT7, FC3, FC1, FC4, FC6, FT8, FT10, T7, C5, C3, C1, C2, C4, C6, T8, TP9, TP7, CP5, CP3, CP1, CPz, CP2, CP4, CP6, TP8, TP10, P7, P5, P1, Pz, P2, P4,... | PMC10530694 | ||
3.2.3. Eye Condition (Factor 3) | The eye condition factor displayed a significant effect in all the studied electrodes in the exposure and post-exposure periods when compared with the baseline period ( | PMC10530694 | ||
3.2.4. Interaction among Factors | There were no significant interactions among the studied factors aside from a few electrodes in specific factor combinations ( | PMC10530694 | ||
3.3. Theta Spectral Power | PMC10530694 | |||
3.3.1. 5G Exposure (Factor 1) | Based on the three-way ANOVA results, the 5G factor did not modify the PSD values of theta waves (Regarding the baseline-corrected data and the 5G factor, the one-way ANOVA revealed no significant difference in the overall analysed electrodes except for the EC condition in P2 ( | PMC10530694 | ||
3.3.2. Time Period (Factor 2) | Following three-way ANOVA, the only significant differences were for P8 ( | PMC10530694 | ||
3.3.3. Eye Condition (Factor 3) | The results of the eye condition variable of the three-way ANOVA showed that 57 out of 64 electrodes were significantly different in the exposure and post-exposure periods compared with the baseline (F7, F5, F3, F1, Fz, F2, F4, F6, F8, FT9, FT7, FC5, FC3, FC1, FC2, FC4, FC6, FT8, FT10, T7, C5, C3, C1, Cz, C2, C4, C6, T... | PMC10530694 | ||
3.3.4. Interaction among Factors | Only some random electrodes showed significant interactions among the studied factors ( | PMC10530694 | ||
3.4. Delta Spectral Power | PMC10530694 | |||
3.4.1. 5G Exposure (Factor 1) | Based on the three-way ANOVA, all electrodes showed a non-significant difference in delta PSDs under “real” and “sham” exposure conditions in the exposure and post-exposure periods ( | PMC10530694 | ||
3.4.2. Time Period (Factor 2) | We found that 58 of 64 electrodes showed significant differences due to the time period in the three-way ANOVA when we compared the baseline and post-exposure periods (Fp1, Fp2, AF7, AF3, AFz, AF4, AF8, F7, F5, F3, F1, Fz, F2, F4, F6, F8, FT9, FT7, FC5, FC3, FC1, FC2, FC4, FC6, FT8, T7, C5, C3, C1, Cz, C2, C4, C6, T8, ... | PMC10530694 | ||
3.4.3. Eye Condition (Factor 3) | This factor significantly altered the delta brain waves in both exposure (Fp2, FT7, FC5, FC3, FC1, FC2, FC4, FC6, FT8, C5, C3, C1, C2, C4, C6, T8, TP9, TP7, CP5, CP3, CP1, CP4, CP6, TP8, TP10, P7, P5, P3, P1, Pz, P2, P4, P6, P8, PO7, PO3, PO4, PO8, O1, O2, and Iz) and post-exposure (Fp1, FC4, FC6, FT8, FT7, FC3, C5, C3... | PMC10530694 | ||
3.4.4. Interaction with 5G | As shown in | PMC10530694 | ||
4. Discussion | In this study, we explored the effects of 3.5 GHz, representing one of the earliest exploited 5G bands, via the EEG of healthy human volunteers. Thirty-four participants took part in two triple-blinded, “real” and “sham” exposure sessions. The latter were randomised and counterbalanced in a wake-rested state, where the... | PMC10530694 | ||
5. Conclusions | Our statistical analysis revealed an overall non-significant difference in beta, alpha, theta, and delta brain oscillations relative to 5G exposure. However, a few electrodes in the baseline-corrected exposure and post-exposure periods exhibited significant modulation corresponding to the eye condition only in the alph... | PMC10530694 | ||
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC10530694 | ||
Author Contributions | Conceptualisation, B.S.; methodology, L.J., L.Y.-C., L.H., P.M. and P.L.; investigation, L.J.; software, L.Y.-C., L.H. and P.L.; validation, B.S., L.Y.-C. and P.L.; formal analysis, L.J., L.Y.-C. and P.L.; resources, L.Y.-C., L.H., P.M. and P.L.; data curation, L.J. and L.Y.-C.; writing—draft preparation, L.J.; writing... | PMC10530694 | ||
Institutional Review Board Statement | -20 | The study was conducted in accordance with the Declaration of Helsinki and approved by the French national ethical committee of “CPP Sud-Ouest et Outre-Mer 1” (protocol code n° 2020-A03127-32 [ID RCB] and 1-20-097 ID 10481 [ID CPP], approved on 15 March 2021). | PMC10530694 | |
Informed Consent Statement | Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the participants to publish this paper. | PMC10530694 | ||
Data Availability Statement | The data presented in this study are available on request from the corresponding author. The data are not publicly available due to confidentiality and privacy considerations. | PMC10530694 | ||
Conflicts of Interest | Neither the authors nor their collaborators declare any conflict of interest. Nevertheless, the opinions expressed are those of the authors and not necessarily those of the granting authorities, which cannot be held responsible for them. | PMC10530694 | ||
Appendix A | The beta band outcomes after three-way repeated-measures analysis of variance (ANOVA). Baseline values were compared with the exposure (The alpha band outcomes after three-way repeated-measures analysis of variance (ANOVA). Baseline values were compared with the exposure (The theta band outcomes after three-way repeate... | PMC10530694 | ||
References | The experimental protocol was preceded by a volunteer preparation phase of approximately 60 min. The protocol included three exposure conditions: the pre-exposure (Baseline), “real” or “sham” exposure, and post-exposure periods. Each exposure and post-exposure period contained 2–3 runs of recording phases that started ... | PMC10530694 | ||
Background | The cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose cotransporter-2 inhibition for 6 months with empagliflozin was associated with a significant reduction in left v... | PMC10303338 | ||
Methods | coronary artery disease | TYPE 2 DIABETES, CORONARY ARTERY DISEASE | A total of 97 patients with type 2 diabetes and coronary artery disease were randomized to empagliflozin (10 mg/d) or matching placebo for 6 months. The study cohort was divided into those whose baseline LVMi was ≤ 60 g/m | PMC10303338 |
Results | Baseline LVMi was 53.3 g/m | PMC10303338 | ||
Conclusions | REGRESSION | Patients with higher LVMi at baseline experienced greater LVM regression with empagliflozin. | PMC10303338 | |
Keywords | PMC10303338 | |||
Background | cardiovascular and renal benefits, T2D, type 2 diabetes, LVH | LVH, TYPE 2 DIABETES, SUDDEN DEATH, LEFT VENTRICULAR HYPERTROPHY | Sodium-glucose transport protein 2 inhibitors (SGLT2i) have shown marked cardiovascular and renal benefits in patients with type 2 diabetes (T2D) [There have been many suggested mechanisms to explain the cardiovascular benefits associated with SGLT2i [Left ventricular hypertrophy (LVH) is an established predictor of po... | PMC10303338 |
Methods | SECONDARY | A detailed description of the design and primary results of the EMPA-HEART CardioLink-6 trial has been published previously [Given that the median baseline LVMi for the empagliflozin-assigned group was 58 kg/mOur secondary analyses included assessment of the relationship between baseline LVMi and changes in left ventri... | PMC10303338 | |
Statistical analyses | Normality of continuous variables was tested with the Skewness and Kurtosis test and examined with visual inspection of a histogram. Continuous variables are reported as medians with interquartile ranges (IQR) or mean ± standard deviation (SD); frequencies and percentages are used to describe categorical data. Continuo... | PMC10303338 | ||
Results | PMC10303338 | |||
Baseline characteristics | TIA, high-density lipoprotein | TIA, TRANSIENT ISCHEMIC ATTACK | Upon stratification of the EMPA-HEART cohort, most baseline characteristics were found to be similar between patients with an LVMi ≤ 60 g/m
Baseline characteristics of the EMPA-HEART CardioLink-6 participants as stratified by baseline LVMi of ≤ or > 60 g/mData are presented as either frequency (%) or median (IQR).ACEi,... | PMC10303338 |
Primary outcomes | LVMi ≤ | REGRESSION, TYPE 2 DIABETES MELLITUS | The effect of empagliflozin on LVMi regression over 6 months was significantly different between patients with a baseline LVMi ≤ 60 g/m
Treatment with empagliflozin (10 mg/d) and 6-month change in LVMi stratified by baseline LVMi of ≤ 60 g/m*ANCOVA model adjusted for duration of type 2 diabetes mellitus, glucose (rando... | PMC10303338 |
Secondary outcomes | In analyses evaluating the relationship of baseline LVMi and change in LVESVi from baseline to 6 months, we observed no significant association (
Association between treatment with empagliflozin (10 mg/d) and 6-month changes in LVESVi, LVEDVi, and LVEF stratified by baseline LVMi of ≤ 60 g/mLVEDVi; left ventricular end... | PMC10303338 | ||
Discussion | diabetes, T2D, LVH, g/mReductions | ACUTE MI, HEART FAILURE, LVH, DIABETES | In this exploratory sub-analysis of the EMPA-HEART CardioLink-6 trial, we evaluated the influence of baseline LVMi on cardiac reverse remodelling with empagliflozin. Our analysis yielded the key finding that patients with a baseline LVMi > 60 g/mReductions in LVM are associated with cardiovascular risk reduction and im... | PMC10303338 |
Conclusions | In conclusion, patients with larger LVMi at baseline experienced significantly greater cardiac reverse remodelling with empagliflozin than patients with a lower LVMi at baseline. Studies with larger cohorts and longer follow-ups are warranted to investigate the influence of baseline LVM on SGLT2i-mediated cardiac rever... | PMC10303338 | ||
Acknowledgements | Not Applicable. | PMC10303338 | ||
Authors’ contributions | MH | Project conception (PP, CDM, ATY, KAC, SV), Data analysis (MH), Data Interpretation (PP, MH, CDM, SV), Original Draft (PP, SV). All authors provided critical review and approved the final manuscript for submission. | PMC10303338 | |
Funding | Pain | This work was supported by an unrestricted investigator-initiated study grant from Boehringer Ingelheim. CDM is supported by a Merit Award from the University of Toronto Department of Anesthesiology and Pain Medicine and holds the Cara Phelan Chair in Critical Care at St. Michael’s Hospital-Unity Health Toronto. KAC ho... | PMC10303338 | |
Data Availability | The datasets analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request. | PMC10303338 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.